Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Comment by mercedesmanon May 13, 2023 10:35pm
151 Views
Post# 35447194

RE:RE:RE:RE:Ok let’s say they get to 90…

RE:RE:RE:RE:Ok let’s say they get to 90…

Not a proud record for Seto - that's for sure. 

Far be it from me to defend him, however you're forgetting about the Gorf campaign in 2022 when the sp reached .61 

Seto and the Board could easily improve things if they chose to ( IMH&EO) by upgrading the US listing in order to attract more US interest and lower the cost of capital on future financings. 

Getting some better US analyst & IR coverage would also help. 

There are only two plausible explanations for why they do not .

So one can successfully counter the dilution by buying shares at well below market & financing prices during the multi-Alias FUD campaign times.  Like say now for instance. 

This way you preserve and increase your share of the ultimate ( and inevitable?) payday  


MM 

<< Previous
Bullboard Posts
Next >>